Literature DB >> 19448164

The G1691A mutation of the factor V gene (factor V Leiden) and the G20210A mutation of the prothrombin gene as risk factors in thrombotic microangiopathies.

Christoph Sucker1, Christine Kurschat, Gerd R Hetzel, Bernd Grabensee, Beate Maruhn-Debowski, Robert Loncar, Ljerka Ostojic, Ruediger E Scharf, Rainer B Zotz.   

Abstract

Factor V Leiden (FVL) mutation and prothrombin G20210A mutation are common hereditary risk factors for venous thrombosis. In the current study, 40 patients (mean age +/- standard deviation, 35 +/- 11 years) and 764 healthy control subjects (mean age +/- standard deviation, 37 +/- 14 years) were enrolled to assess the potential role of these mutations in the manifestation of thrombotic microangiopathies. Compared with controls, neither the heterozygous FVL mutation (7.5% vs 8.5%; P = 1) nor the heterozygous prothrombin mutation (2.5% vs 2.8%; P = 1) was more prevalent in the patients. The findings do not support a significant role of FVL and prothrombin mutations as risk factors for the manifestation of thrombotic microangiopathies. Thus, screening for these mutations does not allow the identification of individuals at increased risk for these rare thrombotic disorders.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19448164     DOI: 10.1177/1076029607311778

Source DB:  PubMed          Journal:  Clin Appl Thromb Hemost        ISSN: 1076-0296            Impact factor:   2.389


  2 in total

1.  Macrovascular thrombosis in critically ill patients with thrombotic micro-angiopathies.

Authors:  Laurent Camous; Agnès Veyradier; Michael Darmon; Lionel Galicier; Eric Mariotte; Emmanuel Canet; Nathalie Parquet; Élie Azoulay
Journal:  Intern Emerg Med       Date:  2012-10-07       Impact factor: 3.397

2.  The frequency of factor V Leiden and prothrombin G20210A mutations in Slovak and Roma (Gypsy) ethnic group of Eastern Slovakia.

Authors:  Alexandra Bôžiková; Dana Gabriková; Adriana Sovičová; Regina Behulová; Soňa Mačeková; Iveta Boroňová; Eva Petrejčíková; Miroslav Soták; Jarmila Bernasovská; Ivan Bernasovský
Journal:  J Thromb Thrombolysis       Date:  2012-10       Impact factor: 2.300

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.